Nektar Therapeutics (NKTR) 옵션

NKTR.................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR...................................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR....................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

Any news? why the jump? anybody...

NKTR......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR....................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR...READY TO BREAK OUT!

NKTR............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR.........................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR new 52 week high

NKTR under $2

NKTR......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR new 52 hi

NKTR here we go. Every time I go higher with my bench press this stocks follows

NKTR setting up here

NKTR...MASSIVE VOLUME

NKTR...PUSHING TO THE TOP OF THE WEEKLY CLOUD....WILL SHE BREAK FOR BLUE SKY!!!

NKTR........................................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR new 52 hi

NKTR new 52 hi

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

NKTR.......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR 10Q March 4

NKTR new 52 week low

NKTR new 52 week low

Stock is in the toilet again they need an actual settlement from LLY go get the stock moving and so far crickets.

Nice stock options 0.68 @ 85,000 shares

Holding up amazingly well,might continue up

NKTR: Now suing Eli Lilly, in conjunction with today's earlier (Dermatitis) news package.

NKTR: This one ain't over until the FAT PHARMACISTS sing!!

NKTR: Huge numbers of Peeps MISSED your brilliant pick here today, Dude!!! (Talk about 'easy money'!!)

$NKTR - 👆Up 15.8% Pre-Market/ Current Price $0.61
Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in '22 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

cheap

cheap

pincher chart on the daily and weekly, I think this could easily run to $1.50

Hmmm just crickets around here, I don’t mind arriving early to the party

NKTR -24%/AH on_termination_of Bempeg program following phase-3 failures in RCC and bladder cancer:

https://finance.yahoo.com/news/nektar-bristol-myers-squibb-announce-203000621.html Nektar Therapeutics and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. These studies and all other ongoing studies in the program will be discontinued. Bempeg previously failed in a phase-3 trial in combination with Opdivo in melanoma (#msg-168191364), so today’s news is three strikes and you’re out!

Rarely has a cancer drug failed so utterly and completely to live up to initial expectations (#msg-138532013). NKTR’s share price is down 96%(!) from its 2018 high.

Ouch Ouch
how it hurts here!
I don't even see a reason to hope it goes up!
How much cash do they have?
But that's enough until the end of 2024 if that's okay ...
THE MANAGER OF NEKTAR THERAPEUTICS SAYS TO PREPARE A PLAN THAT HAS THE OBJECTIVE OF ESTABLISHING THE MINIMUM CASH TRACK UNTIL AT LEAST 2024 - CONF. CALL
As the drug fails to meet any of its goals, Nektar said he would consider curbing his cash spending, which was about $ 800 million at the end of December.


Last week, brokerage agency Oppenheimer estimated that worldwide un-risk-adjusted bempegaldesleukin sales could reach $ 3.7 billion in 2038. (news)

I know of one recently approved that will do 3B by 2026

NKTR’s Bempeg fails as addend to Opdivo in first-line melanoma:

https://finance.yahoo.com/news/bristol-myers-squibb-nektar-announce-105900961.html Bristol Myers Squibb and Nektar Therapeutics today announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma. Following a review of the study for efficacy and safety by an independent Data Monitoring Committee (DMC), Bristol Myers Squibb and Nektar were informed that the study did not meet the primary endpoints of progression-free survival (PFS) and objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR). The DMC notified the companies that the third primary endpoint of overall survival (OS) did not meet statistical significance at the first interim analysis.

Given there was no additional clinical benefit in the doublet therapy arm compared to the monotherapy arm for the primary endpoints of PFS and ORR, and based on the data reviewed by the DMC, the companies have decided to unblind the trial and to perform no additional analyses for the OS endpoint.

Additionally, based on the results from PIVOT IO-001, the companies have also made the decision to discontinue enrollment and unblind the ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma.

NKTR +18% on clinical-trial_collaboration_testing Bempeg+Keytruda in_H&N_cancer:

https://finance.yahoo.com/news/nektar-announces-agreement-phase-2-130000352.html

NKTR is receiving no cash from MRK—only free drug for use in the trial. Rather, unding for the trial is being provided by NKTR’s financing deal with SJC Pharma (https://finance.yahoo.com/news/nektar-announces-collaboration-sfj-pharmaceuticals-125900283.html ).

Note that the 3-year PD-(L)1 exclusivity period of the BMY/NKTR collaboration, which was announced on 2/14/18, has now expired, enabling NKTR to test Bempeg with any PD-(L)1 agent of its choosing.

p.s. Even after today’s pop, NKTR’s share price is down about 70% from the day of the BMY announcement three years ago.

* * $NKTR Video Chart 01-15-2020 * *

Link to Video - click here to watch the technical chart video

Comments on the JPM webcast: #msg-153299506.

We talk about NKTR a little on #board-1418.

On what board are people discussing Nektar ?

Yea, bloody taa for !?
I will check back. Those were shot down before I could focus on them. It’s just that one ticker.
A big pharm company is going to buy 11% of a biotech company.
Whatever you do
Find it.
Two day jump could mean over 50% growth before all the old-timers start jumping out because they were holding this in 1912. BC :)
Im an old timer so I can say this.
Dont miss this one!
And please dont let me miss.
I have an entire day on this :(

Once we are free of that, all of the new people will be coming in by Thursday.

Come on people? It’s really important.

Well if that wasn’t the strangest thing on the planet?

My plan was to research the heck out of this thing and share it with who is on this weekend.

This way we can start Monday ahead of the pac.

There really are only two questions that I would like answers to. This company of course and it’s future and of course what my other message said. Much obliged and whatever I find out, it stays right here.

I have been doing a lot of studying on this company. I know that we are closer to the 52 week wow than the high. This sector is supposed to be picking up in this company looks pretty decent. What can we expect as far as mergers or stock forecast for 2020? Pretty legitimate not asking for million dollar tickers...

Where are we and where are we going....